Healio
›
Cardiology
›
News
›
Publication Exclusives
-
Pharmacology Consult
-
-
Cardiology Today, May 2013
Kathleen A. Lusk, PharmD, BCPS
-
It has been established that resistant hypertension is associated with increased CV morbidity and mortality. Resistant hypertension is defined as elevated...More
»
-
Pharmacology Consult
-
-
Cardiology Today, April 2013
Daniel F. Miller, PharmD BCPS
-
In October, CMS started to impose financial penalties on hospitals with excessive 30-day readmission rates for acute MI, pneumonia and HF. This reality...More
»
-
Pharmacology Consult
-
-
Cardiology Today, March 2013
Yana Labinov, PharmD; Robert DiDomenico, PharmD
-
Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor, such as clopidogrel, is indicated for up to 1 year in patients with ACS and those undergoing...More
»
-
Pharmacology Consult
-
-
Cardiology Today, February 2013
Abigail Plummer, PharmD; Augustus Hough, PharmD, BCPS
-
Historical use of colchicine, or its precursors, dates back several thousand years, with reports appearing in records from ancient Egyptians, Greeks and...More
»
-
Pharmacology Consult
-
-
Cardiology Today, December 2012
Meredith Grycki, PharmD; Douglas L. Jennings, PharmD, BCPS (AQ-CV)
-
Coronary drug-eluting stents were first approved for use in the United States in 2003 after proof of efficacy for reduced target vessel failure and target...More
»
-
Pharmacology Consult
-
-
Cardiology Today, November 2012
Larry Lopez, PharmD
-
Can dabigatran cause clots? On the surface, such a question seems illogical. One may wonder how a drug can cause the problem that it is supposed to treat...More
»
-
Pharmacology Consult
-
-
Cardiology Today, October 2012
Michael Brenner, PharmD, BCPS
-
Office or clinic BP is the most commonly used BP measurement to assist with the management of hypertension. However, clinic BP measurement may...More
»
-
Pharmacology Consult
-
-
Cardiology Today, September 2012
Chris Domenico, PharmD candidate; Cynthia Sanoski, PharmD, BCPS, FCCP
-
Drugs that prolong the QT interval may increase the risk for developing torsades de pointes (TdP). A variety of cardiac and noncardiac medications can...More
»
-
Pharmacology Consult
-
-
Cardiology Today, August 2012
Jingyang Fan, PharmD, BCPS
-
ACE inhibitors (or angiotensin receptor blockers) and beta-blockers are the foundation of pharmacologic treatment for HF, but these agents only partially...More
»
-
Pharmacology Consult
-
-
Cardiology Today, July 2012
John Noviasky, PharmD, BCPS; Michael Kelberman, MD, FACC
-
New medications to manage HF are few and far between. So, when nesiritide came along, the HF community was excited. The connection between the initial...More
»